Harvard University



CANCER IMMUNOLOGY PROGRAMIMMUNOTHERAPY TOXICITY SPOREREQUEST FOR PROPOSALSFor Translational Research ProjectsDue date: Monday, December 16th, 2019The Cancer Immunology Program of the Dana-Farber/Harvard Cancer Center (DF/HCC) and the Department of Immunology in the Blavatnik Institute at Harvard Medical School (HMS) seek translational research projects for potential inclusion in a new Specialized Program on Research Excellence (SPORE) grant that will focus on Cancer Immunotherapy Related Toxicity. Applicants must be on the faculty at Harvard Medical School or Harvard T.H. Chan School of Public Health at the level of Assistant Professor or higher. Proposals will be accepted from investigators from DF/HCC and HMS, although collaborative projects involving investigators from outside DF/HCC and HMS will be considered, as long as a DF/HCC or HMS-based investigator is involved. While the proposed research can be basic or clinical, bench-to-bedside and bedside-to-bench strategies need to be addressed, since the purpose of this program is to promote translational research. All basic research supported by the SPORE must have a plan for translation into application or studies in humans within the 5 years of the grant proposal. To facilitate this translation, such projects should be co-led by a basic and a clinically oriented scientist.We are seeking pre-applications in the form of a 2-4-page proposal that contains background and relevance, specific aims, research plan (preliminary data, experimental methods), anticipated timeline and plans for translation (see below). These pre-applications will be judged on their scientific merit, translational potential, relevance to cancer patients treated with Immunotherapy (including cell-based therapy such as CAR T cells and immune checkpoint inhibitors), qualifications of the research team, and the potential fit within the overall activities of the DF/HCC, HMS Cancer Immunology Program and the SPORE. Some pre-applications will be selected for presentation at project review sessions to be held in early 2020.Final project selections will be made by the Immunotherapy Toxicity SPORE Leadership Committee in conjunction with its Internal Advisory Board by February 29, 2020. Ultimately, 3-4 projects will be included in the final SPORE application that is due in September 2020. If the SPORE grant is funded, the project awards will be granted at a level of approximately $100,000-150,000 in yearly direct costs for 2-5 years. The awardees will be asked to apply for membership of the DF/HCC Cancer Immunology Program and will be expected to participate in SPORE activities (e.g. meetings, retreats, and research presentations). Women and underrepresented in medicine (URiM) investigators are encouraged to apply.Applications must contain the following components:1. Abbreviated Research Plan including the Specific Aims, Background and Significance, Preliminary Data, and Experimental Methods (not to exceed 3 pages)2. Translational goals of the project, potential application to immunotherapy toxicity and anticipated timeline (1 page)3. List and descriptions of key personnel and roles on the project4. Applicant address; E-mail and telephone contact information.Application packages are due Monday December 16th, 2019 in PDF format. Please contact Carolyn Hoban, ScD with any questions. Please send completed proposal electronically to CHOBAN@mgh.harvard.edu ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download